Medications for diabetic neuropathy

作     者：Griebeler ML Morey-Vargas OL Brito JP 

出 版 物：《中华物理医学与康复杂志》 (Chinese Journal of Physical Medicine and Rehabilitation)

年 卷 期：2015年第37卷第2期

页      面：85-85页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 0832[工学-食品科学与工程（可授工学、农学学位）] 100705[医学-微生物与生化药学] 08[工学] 083202[工学-粮食、油脂及植物蛋白工程] 10[医学] 

主　　题：药物治疗 糖尿病 神经 病变 随机对照试验 醛糖还原酶抑制剂 度洛西汀 试验评估 

摘      要：BACKGROUND AND OBJECTIVE Diabetic neuropathy is a common, long-term complication that can decrease quality of life. While various neuropathic agents are useful for treating this pain, choosing one or the other can be challenging. This systematic review investigated the relative effectiveness of various medications used for the treatment of diabetic *** Databases were reviewed for randomized, controlled trials published between January of 2012 and April of 2014. The trials assessed the efficacy of medications for treating diabetic neuropathy, and compared the medication to placebo or to another *** Sixty-five, randomized, controlled trials, including 27 medications with 12, 632 patients analyzed. By drug class, SNRIs, topical capsaicin, TCAs, and anticonvulsants all resulted in larger and statistically significant reductions in pain, as compared with placebo. Head-to-head trials showed that SNRIs and TCAs reduced pain more than did anticonvulsants and topical capsaicin. Studies that evaluated long-term efficacy found that the aldose reductase inhibitors fidarestat, duloxetine and oxcarbazepine are all more effective than placebo. Indirect and direct comparisons among specific medications revealed greater pain control with carbamazepine, venlafaxine, duloxetine and amitriptyline as compared with *** This systematic review and meta-analysis of pharmacologic interventions for painful diabetic neuropathy found that carbamazepine, venlafaxine, duloxetine and amitriptyline are significantly better than placebo for controlling pain.